BBIO
BridgeBio Pharma, Inc.75.69
+1.18+1.58%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
14.59BP/E (TTM)
-Basic EPS (TTM)
-4.21Dividend Yield
0%Recent Filings
8-K
Positive Phase 3 results for BBP-418
BridgeBio Pharma announced positive Phase 3 interim results for BBP-418 in the FORTIFY study on October 27, 2025, showing a 1.8x increase in glycosylated αDG at three months and sustained gains at 12 months, alongside clinically meaningful improvements in ambulatory and pulmonary function versus placebo. The drug cut serum creatine kinase by 82%, signaling reduced muscle breakdown, and proved well-tolerated. BridgeBio plans an FDA NDA filing in the first half of 2026. Data support a favorable risk-benefit profile for this orphan disease therapy.
8-K
BridgeBio Q2 revenue surges on Attruby
BridgeBio Pharma reported Q2 2025 revenue of $110.6 million, driven by $71.5 million from Attruby net product sales, with 3,751 unique prescriptions written by 1,074 prescribers as of August 1, signaling accelerating adoption in ATTR-CM treatment. New ATTRibute-CM analyses showed a 59% risk reduction in variant patients and 31.6% mortality drop tied to TTR stabilization, bolstering its profile. Phase 3 trials for BBP-418, encaleret, and infigratinib hit enrollment milestones, with topline data due fall 2025 to early 2026. Cash stood at $756.9 million, funding launches amid rising SG&A costs.
10-Q
Q2 FY2025 results
BridgeBio Pharma, Inc. (BridgeBio) and Eidos Therapeutics, Inc. (Eidos) announce Q2 FY2025 financial results. Total revenues were $XX million, up XX% YoY, driven by net product revenues of $XX million from acoramidis (Attruby/Beyonttra) in the U.S. and royalties from international sales. Operating loss was $XX million, with cash and equivalents at $XX million as of June 30, 2025. R&D expenses were $XX million, primarily for ongoing clinical trials. SG&A expenses were $XX million. The company reaffirms guidance for full-year FY2025 revenues of $XX-$XX million and expects to achieve key milestones in Q3. No forward-looking statements are made regarding the royalty agreement.
Eidos Therapeutics, Inc. (Company) and BridgeBio Pharma, Inc. (Parent) have entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP (ARS) and LSI Financing Fund, LP (LSI) dated June 27, 2025. The Company sells to the Purchasers their pro rata shares of royalties from net sales of licensed products (Licensed Products) containing acoramidis (Covered Compound) in the European Union and certain other territories (Territory) under the BBCH License Agreement and Bayer License Agreement (Covered License Agreements). The Purchase Price is $300 million, payable on the Closing Date. The royalties are subject to an annual cap of 60% of royalties paid by Bayer on the first $500 million of annual net sales in the Territory, with a hard cap of 145% of the Purchase Price until July 1, 2031, decreasing thereafter. Payments are directed to a Lockbox Account controlled by the Purchaser Representative. The agreement includes representations, warranties, covenants, and remedies, including security interests in the Lockbox Account and backup collateral. The term ends when the hard cap is reached or upon a change of control or event of default, with a change of control payment equal to the hard cap minus total net amounts received. Indemnification, tax provisions, and governing law under New York are also included.
8-K
Sells EU royalties for $300M
BridgeBio Pharma's subsidiary Eidos sold royalty rights on acoramidis net sales in Europe to Acoramidis Royalty SPV and LSI Financing Fund for $300 million in cash on June 27, 2025. The deal caps purchaser receipts at 60% of royalties on the first $500 million in annual sales, with a hard cap at 145% of the purchase price. This non-dilutive funding bolsters BridgeBio's balance sheet. Change of control triggers a buyout option.
8-K
BridgeBio approves governance tweaks
BridgeBio Pharma stockholders approved key governance updates at the June 20, 2025 annual meeting, including an officer exculpation amendment limiting liability for certain executives under Delaware law, effective June 23. They also ratified Deloitte as auditors, endorsed executive pay, and boosted the 2021 incentive plan by 5 million shares to fuel talent retention. Directors were elected with solid support. This bolsters leadership protections while expanding equity tools.
ABVC
ABVC Biopharma, Inc.
2.06-0.01
BBOT
BridgeBio Oncology Therapeutics
11.85-0.15
BIOA
BioAge Labs, Inc.
12.51+0.05
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
FBIO
Fortress Biotech, Inc.
3.51+0.19
IBIO
iBio, Inc.
2.06+0.23
IBRX
ImmunityBio, Inc.
2.16-0.06
INBX
Inhibrx Biosciences, Inc.
81.57+5.36
INMB
INmune Bio Inc.
1.89-0.02
LIANY
LianBio
0.09+0.00